# Sarayut Lucien Geater

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/sarayut-lucien-geater/

## Facts

| Field | Value |
| --- | --- |
| Citations | 22,326 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 36 |
| i10-index | 67 |
| Last Known Institution | Prince of Songkla University |
| OpenAlex ID | https://openalex.org/A5053546904 |
| ORCID iD | https://orcid.org/0000-0002-3494-8268 |
| Works | 148 |

## Researcher papers

- [Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations](https://scholariq.org/papers/phase-iii-study-of-afatinib-or-cisplatin-plus-pemetrexed-in-patients-with/)
- [Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial](https://scholariq.org/papers/afatinib-versus-cisplatin-plus-gemcitabine-for-first-line-treatment-of-asian/)
- [Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC](https://scholariq.org/papers/atezolizumab-for-first-line-treatment-of-pd-l1-selected-patients-with-nsclc/)
- [Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials](https://scholariq.org/papers/afatinib-versus-cisplatin-based-chemotherapy-for-egfr-mutation-positive-lung/)
- [First-line ceritinib versus platinum-based chemotherapy in advanced ALK -rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study](https://scholariq.org/papers/first-line-ceritinib-versus-platinum-based-chemotherapy-in-advanced-alk/)
- [Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6](https://scholariq.org/papers/clinical-activity-of-afatinib-in-patients-with-advanced-non-small-cell-lung/)
- [Osimertinib with or without Chemotherapy in <i>EGFR</i> -Mutated Advanced NSCLC](https://scholariq.org/papers/osimertinib-with-or-without-chemotherapy-in-i-egfr-i-mutated-advanced-nsclc/)
- [Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study](https://scholariq.org/papers/durvalumab-as-third-line-or-later-treatment-for-advanced-non-small-cell-lung/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)

## Researcher university

- [Prince of Songkla University](https://scholariq.org/institutions/prince-of-songkla-university/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.